As of 10:04 on March 27, 2025, the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) rose 1.33%, the constituent stocks Weigao (01066) rose 9.22%, 3SBio (01530) rose 7.95%, Innovent Biologics (01801) rose 6.27%, WuXi XDC (02268), Federated Pharmaceutical (03933) and other stocks followed suit. Hong Kong Pharmaceutical ETF (159718) rose 1.46%, the latest price was 0.69 yuan, and the intraday turnover has reached 11.2523 million yuan, with a turnover rate of 5.62%.

As of 09:59 on March 27, 2025, the CSI Pharmaceutical and Medical Device Innovation Index (931484) fell by 0.26%. In terms of constituents, Allist (688578) led by 1.26%, Baili Tianheng (688506) rose 1.22%, and Pharmaron (300759) rose 0.83%; Xingqi Eye Medicine (300573) led the decline by 3.44%, Aimeike (300896) fell by 2.78%, and Huahai Pharmaceutical (600521) fell by 1.50%. Medical Innovation ETF (516820) is long and short, the latest price is 0.34 yuan, and the intraday turnover has reached 7.0824 million yuan, with a turnover rate of 0.41%.

In the long run, as of March 26, 2025, Hong Kong stock pharmaceutical ETFs have risen by 1.49% in the past two weeks, ranking 2/4 of comparable funds. The medical innovation ETF has risen by 12.96% in the past six months.

In terms of scale, the latest scale of medical innovation ETF reached 1.756 billion yuan.

In terms of fund inflow, the latest net inflow of medical innovation ETF was 6.1498 million yuan. In the long run, there have been 4 net inflows of funds in the past five trading days, with a total of 17.4947 million yuan of "gold absorption", and an average daily net inflow of 3.4989 million yuan.

The data shows that leveraged funds continue to be deployed. The latest financing purchase amount of medical innovation ETF reached 4.7764 million yuan, and the latest financing balance reached 79.5792 million yuan.

The

roundtable of the 2025 Annual Conference of the China Development Forum (CDF) was held in Beijing. Heads of relevant departments and enterprises in the pharmaceutical field attended the meeting, emphasizing the need to deepen the reform of the medical and health system in the process of Chinese-style modernization and vigorously promote the construction of a healthy China.

Everbright Securities said that since 2024, a number of favorable policies have focused on the field of innovative drugs, covering multiple dimensions such as payment, financing, review and assessment, supporting the commercialization and R&D of innovative drugs in the whole chain, demonstrating the great importance attached to innovative drugs. With the gradual implementation of policies, the development of innovative drugs is expected to accelerate, and the prospects of the biomedical sector continue to be optimistic.

The CSI Hong Kong Stock Connect Medical and Health Composite Index selects 50 securities of listed companies in the medical and health industry with good liquidity and large market capitalization from the Hong Kong Stock Connect as index samples to reflect the overall performance of the securities of medical and health listed companies within the scope of Hong Kong Stock Connect.

According to the data, as of February 28, 2025, the top 10 weighted stocks of the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) are BeiGene (06160), WuXi Biologics (02269), Innovent Biologics (01801), Akeso Biologics (09926), JD Health (06618), CSPC Pharmaceutical Group (01093), Sino Biopharma (01177), Ali Health (00241), Zai Lab (09688), Sinopharm ( 01099), the top 10 weighted stocks accounted for 59.55% of the total.

Hong Kong Pharmaceutical ETF (159718), OTC Connect (Ping An CSI Hong Kong Pharmaceutical ETF Connect A: 019598; Ping An CSI Hong Kong Pharmaceutical ETF Connect C: 019599).

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of February 28, 2025, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec (603259), Mindray Medical (300760), Hengrui Pharmaceutical (600276), Aier Ophthalmology (300015), United Imaging Healthcare (688271), Kelun Pharmaceutical (002422), Changchun High-tech (000661), Huadong Medicine (000963), and Zhifei Biotechnology (300122). ), Pharmaron (300759), the top 10 weighted stocks together accounted for 66.9%.